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Several peptides sharing high sequence homology with lactoferricin B (Lf-cin B) were generated from bovine
lactoferrin (Lf) with recombinant chymosin. Two peptides were copurified, one identical to Lf-cin B and
another differing from Lf-cin B by the inclusion of a C-terminal alanine (lactoferricin). Two other peptides were
copurified from chymosin-hydrolyzed Lf, one differing from Lf-cin B by the inclusion of C-terminal alanyl-
leucine and the other being a heterodimer linked by a disulfide bond. These peptides were isolated in a single
step from chymosin-hydrolyzed Lf by membrane ion-exchange chromatography and were purified by reverse-
phase high-pressure liquid chromatography (HPLC). They were characterized by N-terminal Edman sequenc-
ing, mass spectrometry, and antibacterial activity determination. Pure lactoferricin, prepared from pepsin-
hydrolyzed Lf, was purified by standard chromatography techniques. This peptide was analyzed against a
number of gram-positive and gram-negative bacteria before and after reduction of its disulfide bond or
cleavage after its single methionine residue and was found to inhibit the growth of all the test bacteria at a
concentration of 8 mM or less. Subfragments of lactoferricin were isolated from reduced and cleaved peptide
by reverse-phase HPLC. Subfragment 1 (residues 1 to 10) was active against most of the test microorganisms
at concentrations of 10 to 50 mM. Subfragment 2 (residues 11 to 26) was active against only a few microor-
ganisms at concentrations up to 100 mM. These antibacterial studies indicate that the activity of lactoferricin
is mainly, but not wholly, due to its N-terminal region.
Lactoferrin (Lf) is a bilobate iron-binding glycoprotein with
a mass of approximately 80 kDa and is an antimicrobial com-
ponent of milk and other exocrine secretions (27, 32). In se-
rum, Lf is released by activated neutrophils during the inflam-
matory response, and there is in vivo evidence that it stimulates
neutrophil accumulation and adhesion (33). Lf is also reported
to be a regulator of myelopoiesis (13), although the mechanism
is unclear (20). A strong iron-binding capability is implicated in
its role as an effector of slow-cycle serum iron metabolism,
where serum iron is bound by Lf and is subsequently taken up
by receptors on macrophages and the liver for transfer to
ferritin (10, 42, 43).
Lf is active against a wide selection of pathogenic bacteria
(5, 14, 17, 38). Lf’s strong iron-binding capacity is implicated in
the antimicrobial mechanism, effectively withholding this es-
sential element from otherwise proliferative microorganisms
(17). There is also evidence indicating a direct killing effect,
unrelated to iron binding, which is mediated by binding to the
surfaces of susceptible organisms (4). The interaction between
Lf and gram-negative bacteria releases significant levels of
lipopolysaccharide from the outer membrane (19). This re-
lease, compromising outer membrane permeability, increases
bacterial susceptibility to other antimicrobial factors such as
lysozyme (18). Currently, there are no molecular studies which
define Lf’s antimicrobial mechanism, even though its three-
dimensional structure is well characterized (3).
The stability of lactoferrin and the maintenance of its anti-
bacterial character have been studied under a range of condi-
tions. As a constituent of milk, Lf is subject to the enzymes and
environment of the infant gut. Human Lf, absorbed via recep-
tors in the gut lining, has been isolated structurally and func-
tionally intact from the urine of infants fed human milk (22). A
number of enzymes have since been used to test the functional
integrity of Lf. The iron-binding capacity and antibacterial
activity of bovine apolactoferrin are abolished by treatment
with chymotrypsin or trypsin (11, 12). Treatments of bovine Lf
with papain, actinase AS, protease P, protease A, or bioprase
are also reported to eliminate both iron-binding and antimi-
crobial activities (38).
During studies to assess the heat stability of Lf, it was found
that the protein was thermostable at acidic pH (1), but under
more extreme conditions (1208C, pH 2) it produced a hydro-
lysate that retained antimicrobial activity independent of iron
binding (35). Treatment of the protein with pepsin is also
reported to yield a hydrolysate which, while unable to bind
iron, remains antibacterially active (40). An active peptide,
lactoferricin B (Lf-cin B), was subsequently isolated from the
hydrolysate and identified as residues 17 to 41 of bovine Lf (7).
Lf-cin B is highly basic, has a single disulfide bond and no
iron-binding capacity, and is active against a wide range of
microorganisms, including bacteria, yeast, and fungi (6, 8, 9, 44,
47). Peptides from the N-terminal region of Lf are also re-
ported to have other biological activities. Two peptides (resi-
dues 39 to 42 and residues 20 to 37 of human Lf) have anti-
thrombotic properties (26, 28, 46), while the first 14 N-terminal
residues reportedly affect hepatic uptake of the protein (48).
Fluorescent probes and peptide synthesis have identified a
neutrophil-binding region on the N terminus (residues 4 to 52)
of human Lf (25). These studies highlight the importance of
Lf’s N-terminal region to biological functions which do not
directly involve iron binding.
Chymosin, like pepsin, is an aspartyl proteinase and demon-
strates activity similar to that of pepsin at low pH. Previously,
a study on the susceptibility of Lf to chymosin reported that
native Lf is not hydrolyzed by the enzyme at pH 6.3 to 6.5 (37).
In the present studies chymosin has been used under acidic
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conditions to generate several Lf-cin B-like peptides. We have
used both membrane ion-exchange and standard chromato-
graphic techniques to isolate antibacterially active lactoferricin
from bovine Lf, and preliminary structural studies explored the
antibacterial elements of the peptide. Purified lactoferricin was
variously reduced at its single disulfide bond, cleaved at a
centrally positioned peptide bond, or both reduced and cleaved
to yield two subfragments. The antibacterial activities of these
derivatives were compared to that of the intact peptide.
MATERIALS AND METHODS
Materials. Enterotoxigenic Escherichia coli L361 and E. coliO:9, isolated from
piglets with neonatal or postweaning scours, were obtained from the Regional
Veterinary Laboratory (Wagga Wagga, Australia). Pseudomonas fluorescens was
isolated from raw milk, Bacillus cereus ACM 446 was obtained from the Univer-
sity of Queensland (Brisbane, Australia), and Salmonella Salford IMVS 1710 was
obtained from the Institute of Medical and Veterinary Science (Adelaide, Aus-
tralia). Listeria monocytogenes NCTC 7973 and Staphylococcus aureus NCTC
6571 were from the National Collection of Type Cultures (London, England). All
bacteria were maintained on peptone yeast extract agar slants at 48C and were
subcultured every 2 months to ensure viability. Bovine Lf was purified from
cheddar cheese whey by cation-exchange chromatography on S-Sepharose Fast
Flow by the method of Law and Reiter (24). For reverse-phase high-pressure
liquid chromatography (RP-HPLC) solvent A consisted of 0.1% trifluoroacetic
acid (TFA; Auspep, Parkville, Australia), and solvent B was 0.09% TFA and
90% acetonitrile (Fisons Pty. Ltd., Homebush, Australia). Recombinant chymo-
sin (Chymogen; EC 3.4.23.4) was a gift from R. Foo of Christian Hansen’s
Laboratory Pty. Ltd. (Bayswater, Australia). Pepsin A (EC 3.4.23.1) was ob-
tained from Sigma Chemical Co. (St. Louis, Mo.).
Generation of chymosin-hydrolyzed Lf and isolation of lactoferricins. Chymo-
sin solution was dialyzed exhaustively against deionized water at 48C to remove
salts and preservatives. After dialysis the enzyme was lyophilized and stored at
48C. Lf (5 g) was dissolved in 200 ml of water, and the solution was adjusted to
pH 3.0 by dropwise addition of 1 M HCl. Recombinant chymosin (200 mg) was
dissolved in the solution, which was incubated at 608C for 1 h. The solution was
cooled to 208C, adjusted to pH 7.0 by dropwise addition of 1 M NaOH, and then
centrifuged at 48C for 15 min at 17,000 3 g. The pellet was discarded. A
Sartobind-S Minisart membrane ion-exchange (MIE) unit (Sartorius GmbH,
Go¨ttingen, Germany) was equilibrated with 10 ml of 10 mM sodium phosphate
buffer (pH 7.0). Chymosin-hydrolyzed Lf (5 ml) was passed through the MIE
unit, which was washed with 5 ml of 10 mM sodium phosphate buffer (pH 7.0).
The MIE unit was then washed with 5 ml of 10 mM sodium phosphate buffer (pH
7.0) containing 2 M NaCl and 10% acetonitrile. The procedure described above
was repeated until 100 ml of chymosin-hydrolyzed Lf had been processed. The
material eluting with the salt washes (retentate) was pooled and acidified to 0.1%
TFA. The acidified material was loaded onto a preparative column (25 by 2.2 cm
[inner diameter; i.d.]; Vydac C18; 15 to 20 mm) which had been equilibrated at 5
ml/min with solvent A at 258C. The column was washed with 100 ml of 20%
solvent B, followed by a 40-min linear gradient to 35% solvent B. Fractions were
collected every 1 min during the gradient, and elution was monitored by mea-
suring the absorbances at 280 and 214 nm. Purified peptides were lyophilized and
were stored at 2208C.
Generation of pepsin-hydrolyzed Lf and isolation of lactoferricin. The gener-
ation of pepsin hydrolysate of Lf followed closely the methods of Tomita et al.
(40). Briefly, 10 g of Lf was dissolved in water and was adjusted to pH 2.5 by
dropwise addition of 1 M HCl. Pepsin (300 mg) was dissolved in the solution,
which was incubated at 378C for 4 h. The reaction was terminated by incubation
of the solution at 808C for 15 min. The solution was cooled to 208C, adjusted to
pH 7.0 by dropwise addition of 1 M NaOH, and then centrifuged at 48C for 15
min at 17,000 3 g. The pellet was discarded. A column (25 by 2.2 cm [i.d.]) of
S-Sepharose Fast Flow resin was equilibrated at 258C and at a flow rate of 2
ml/min with 50 mM sodium phosphate buffer (pH 7.0) containing 10% acetoni-
trile. Pepsin-hydrolyzed Lf was loaded onto the column, and the column was
washed with 50 mM sodium phosphate buffer (pH 7.0) containing 10% aceto-
nitrile. The column was then washed with 50 mM sodium phosphate buffer (pH
7.0) containing 0.5 M NaCl and 10% acetonitrile, followed by a final wash with
50 mM sodium phosphate buffer (pH 7.0) containing 1 M NaCl and 10%
acetonitrile. Bulk fractions were characterized by analytical RP-HPLC as follows.
A small aliquot (10 ml) was acidified to 0.1% TFA and loaded onto an analytical
column (25 by 0.46 cm [i.d.]; Vydac C18, 5 mm) equilibrated with 20% solvent B
at 1 ml/min and 258C; the column was then subjected to a 40-min linear gradient
from 20% solvent B to 50% solvent B. The material identified by analytical
HPLC as containing lactoferricin was acidified to 0.1% TFA and was loaded onto
a preparative column (25 by 2.2 cm [i.d.]; Vydac C18) which had been equili-
brated at 5 ml/min with solvent A at 258C. The column was washed with 100 ml
of 20% solvent B, followed by a 40-min linear gradient to 35% solvent B.
Fractions were collected every 1 min during the gradient, and elution was mon-
itored by measuring the absorbances at 280 and 214 nm. Purified peptide was
lyophilized and stored at 2208C.
Antibacterial assay. The antibacterial assay used was based on the method of
Nonnecke and Smith (30). Incubations for all organisms except P. fluorescens
were done at 378C; P. fluorescens was incubated at 308C. Working inocula of
bacteria were prepared by subculture of isolates from agar slants into Todd-
Hewitt broth and incubation for 16 h. After this time 0.5 ml of the culture was
inoculated into 10 ml of fresh Todd-Hewitt broth, and the mixture was incubated
for a further 6 h. The culture was then diluted in 0.1% peptone to approximately
104 CFU/ml and was used for inoculation of the microassay. Assays were per-
formed in sterile 96-well tissue culture plates (Disposable Products, Technology
Park, Australia). The growth medium contained 1% peptone, 0.05% yeast ex-
tract, and 1% glucose (PYG medium; pH 6.8). Solutions of test peptide were
prepared in filter-sterilized water. To each well was added 190 ml of PYG
medium, 50 ml of peptide solution, and 10 ml of bacterial inoculum. Growth
controls contained sterile water in place of peptide solutions, and blanks con-
tained sterile water in place of both peptide solutions and bacterial inocula. The
plate was covered with a sterile lid and was incubated for 17 h. After incubation
each well was scanned for the absorbance at 620 nm. Antibacterial activity was
expressed as the MIC of peptide required to give no increase in absorbance at
620 nm following incubation. All analyses were performed in duplicate three
times.
Chemical modification of lactoferricin. A method based on that of Allan (2)
was used to cleave the peptide with cyanogen bromide (CNBr). The peptide was
dissolved in 70% acetic acid with CNBr at a molar ratio of 1:100 (peptide:CNBr).
The solution was flushed with nitrogen gas and sealed and was then incubated
overnight at 258C with constant stirring. After the reaction, the solution was
diluted eightfold in water and lyophilized. It was then redissolved in water and
lyophilized again. The dry product was stored at 2208C. Reduction of lactofer-
ricin was carried out by dissolving purified peptide in 250 mM b-mercaptoetha-
nol in 50 mM sodium phosphate buffer (pH 8.0) and heating for 5 min in a
boiling water bath. After reduction, the solution was acidified to 0.1% TFA and
was subjected to RP-HPLC to remove excess b-mercaptoethanol and the di-b-
hydroxyethyl disulfide reaction product. The procedure was as follows. The
acidified sample was loaded onto a preparative RP-HPLC column (25 by 2.2 cm
[i.d.]; Vydac C18) which had been equilibrated at 5 ml/min with solvent A at 258C.
The column was washed with 100 ml of 20% B, followed by a 40-min linear
gradient to 35% solvent B. Fractions were collected every 1 min during the
gradient, and elution was monitored by measuring the absorbances at 280 and
214 nm. Aliquots (50 ml) of each fraction were added to 950 ml of solvent A, and
the solution was analyzed by analytical RP-HPLC. Fractions containing the
reduced peptide were pooled, lyophilized, and stored at 2208C.
RP-HPLC isolation of CNBr fragments of lactoferricin. CNBr-cleaved peptide
was dissolved in 250 mM b-mercaptoethanol in the presence of 50 mM sodium
phosphate buffer (pH 8.0), and the solution was heated for 5 min in a boiling
water bath. The sample was acidified to 0.1% TFA and was purified by prepar-
ative RP-HPLC as described above for reduced lactoferricin. Purified peptides
were lyophilized and stored at 2208C.
MS. The mass of each purified peptide was assessed by mass spectrometry
(MS) by using a PE-SCIEX AP111 triple quadrupole mass spectrometer fitted
with an Ion Spray ion source (PE-SCIEX Instruments, Toronto, Ontario, Can-
ada). Sample (5 ml) was injected into the solvent delivery line (solvent mixture,
45% acetonitrile in 0.05% TFA) of the mass spectrometer operated in the
positive ion mode (Ion Spray voltage,15 kV). Standard scan conditions werem/z
300 to 2,400 in 5 s by using a step of 0.5 atomic mass units. Spectra were collected
by using multichannel averaging at an orifice potential of 70 V. Molecular masses
were calculated by using HyperMass software, and raw data were analyzed
by MacBioSpec, version 1.0.1, and MacSpec, version 3.2, software (PE-SCIEX
Instruments).
N-terminal sequencing. N-terminal sequencing of pure peptides was per-
formed by Edman degradation with an Applied Biosystems 470A protein se-
quencer with an on-line model 120A PTH Analyzer (Applied Biosystems, Foster
City, Calif.). Typically, five cycles were run. Sequencing results were combined
with mass spectral analysis and the full amino acid sequence of bovine Lf (34) in
order to identify the full sequence of each fragment.
RESULTS
Purification and characterization of chymosin-generated
lactoferricins. In an attempt to generate and isolate antimicro-
bial peptides, Lf was hydrolyzed with chymosin at low pH, and
the hydrolysate was passed through a cation-exchange filter
unit. Analytical and preparative loads of Lf hydrolysate were
compared to determine if active peptides might be purified by
displacement chromatography. MIE of analytical (1 ml) and
preparative (5 ml) loads resulted in retentates with markedly
different RP-HPLC profiles (Fig. 1). The analytical retentate
revealed by RP-HPLC a six-peak profile which was reduced to
three in the preparative retentate. Peptides which eluted with
2 M NaCl from the MIE unit under preparative conditions
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were further fractionated by RP-HPLC. Isolation and charac-
terization of the earliest of three RP-HPLC peaks (a) revealed
the copurification of two peptides with identical N termini
(FKCRR) and RP-HPLC retention times. Mass spectral anal-
ysis confirmed the presence of two species with molecular
masses of 3,123 Da (peptide 1A) and 3,194 Da (peptide 1B).
The two peptides appeared to be produced in a ratio of ap-
proximately 1:1 (mass spectral data not shown). The next elut-
ing peak (b) was a single peptide, also with an N terminus of
FKCRR, but having a molecular mass of 3,308 Da (peptide 2).
The last peak (g) was also due to a single species, consisting of
two peptides joined by a disulfide bond (a heterodimer) and
having a molecular mass of 5,850 Da (peptide 3). The two N
termini of the heterodimer were determined by sequencing to
be FKCRR and APRKN. The full sequences of the peptides
are presented in Fig. 2. Antibacterial assays were performed to
determine the activities of the peptides. The peptide mixture
retained by the MIE unit had an MIC of 20 mg/ml for E. coli
under hypotonic conditions. The RP-HPLC-copurified pep-
tides, peptide 1A and peptide 1B, had MICs of 12.5 mg/ml (4
mM). The other two RP-HPLC-purified peptides (peptides 2
and 3) also had MICs of 4 mM (Table 1).
Purification and characterization of pepsin-generated lacto-
ferricin. To generate the antimicrobial peptide lactoferricin, Lf
was enzymatically digested with pepsin. Partial purification of
lactoferricin from the hydrolysate, achieved by cation-ex-
change chromatography, is illustrated in Fig. 3. Final purifica-
tion of the peptide was effected after RP-HPLC; homogeneity
was determined by HPLC (Fig. 4) and mass spectrometry (data
not shown). The average yield of lactoferricin by this method
from a theoretical maximum was 50% (200 mg from 10 g of
Lf). The peptide had a molecular mass of 3,194 Da and an
N-terminal sequence of FKCRR, revealing it to be comprised
of residues 17 to 42 in bovine Lf (FKCRRWQWRMKKLGA
PSITCVRRAFA), with a disulfide bond between Cys3 and
Cys20 of the peptide (Fig. 5). The calculated monoisotopic
molecular mass of the oxidized form of the peptide is 3,193.7
Da. The antibacterial activity of purified lactoferricin was de-
termined against a number of bacteria (Table 2). The peptide’s
apparent MIC ranged from 2 to 8 mM.
Reduction and cleavage of lactoferricin. To determine
whether disruption of its cyclic structure would have an effect
on the antimicrobial activity of lactoferricin, the peptide was
either reduced in the presence of b-mercaptoethanol or
FIG. 1. Analytical RP-HPLC of chymosin-hydrolyzed Lf and MIE retentate
fractions. Samples were brought to 0.1% TFA, and 10 ml was injected onto a
Vydac C18 column (25 by 0.46 cm [i.d.]; solvent A, 0.1% TFA; solvent B, 90%
acetonitrile in 0.09% TFA; equilibration was in 20% solvent B for 5 min; gra-
dient, 20% solvent B to 50% solvent B over 40 min; flow rate, 1 ml/min). A
Sartobind-S Minisart MIE unit was used to fractionate chymosin-hydrolyzed Lf
by using analytical (1 ml) or preparative (5 ml) loads of hydrolysate. (A) Chy-
mosin-hydrolyzed Lf. (B) Analytical MIE retentate. (C) Preparative MIE reten-
tate. Peak a was characterized as peptides 1A and 1B, peak b represents peptide
2, and peak g represents peptide 3.
FIG. 2. Sequences of antibacterial peptides isolated from chymosin-hydro-
lyzed Lf. Primary structures were determined by MS, N-terminal Edman se-
quencing, and reference to the known sequence of bovine Lf (34). Peptides 1A
and 1B copurify during RP-HPLC. Peptide 1A is identified as lactoferricin B (7).
Lines connecting cysteine residues indicate disulfide bonds.
TABLE 1. Antibacterial activities of chymosin-hydrolyzed
Lf and peptides against E. coli L361
Lf or peptide
MICa
mg/ml mM
Native Lf b 1,000 12.5
Chymosin-hydrolyzed Lf b 400
Membrane ion-exchange retentatec 20
Peptides 1A and 1Bd 12.5 4
Peptide 2d 13.2 4
Peptide 3 d 23.4 4
a Defined as the minimum concentration required to inhibit bacterial growth,
measured by monitoring the absorbance at 620 nm.
b Concentrations of 0, 200, 400, 600, 800, and 1,000 mg/ml were used.
c Retentate concentrations of 0, 10, 20, 30, 40, and 50 mg/ml were used.
d Peptide concentrations of 0, 2, 4, 6, 8, and 10 mMwere used. For peptides 1A
and 1B, concentration was based on the total weight of material containing both
components and using an average value of the molecular mass (their molecular
masses differ by 2%).
FIG. 3. S-Sepharose Fast Flow chromatography of pepsin-hydrolyzed Lf.
The supernatant (pH 7.0) from 10 g of pepsin-hydrolyzed Lf was loaded onto a
column (25 by 2.5 cm [i.d.]) and eluted with 50 mM sodium phosphate buffer (pH
7.0) containing 10% acetonitrile at a flow rate of 2 ml/min. A two-step NaCl
gradient (0.5 and 1 M) was used to fractionate the hydrolysate (– – – –). The
fraction containing lactoferricin is indicated by the bar at the top right.
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cleaved with CNBr. Reduction of the peptide’s disulfide bond
resulted in a molecular mass increase of 2, to 3,196 Da. Anal-
ysis of this reduced peptide by RP-HPLC showed an increase
in the retention time, from 20.7 to 22.3 min. Antibacterial
assays comparing the oxidized (untreated) and reduced forms
of lactoferricin were carried out against a number of bacteria.
The MIC of oxidized lactoferricin varied from 2 to 8 mM
(Table 2). Reduction of the disulfide bond did not greatly alter
the peptide’s antibacterial activity (Table 2). Cleavage of oxi-
dized lactoferricin by CNBr in the presence of acetic acid
resulted in a mass of 3,164 Da, a decrease of 30 Da, consistent
with the formation of a homoserine lactone at Met10. The
retention time on RP-HPLC decreased to 19.5 min from 20.7
min. The same reaction carried out in the presence of formic
acid resulted in the formation of two products with masses of
3,164 and 3,192 Da. Analysis by MS-MS suggested that the
second product of CNBr-formic acid cleavage was due to the
reversible esterification of a serine residue (data not shown).
Antibacterial assays with the CNBr-acetic acid-cleaved peptide
demonstrated that this treatment had no measurable effect on
the activity of lactoferricin against a number of bacteria (Table
2).
Fragmentation of lactoferricin. To determine whether the
antibacterial activity of lactoferricin resides in one region of
the peptide or another, CNBr-cleaved lactoferricin was re-
duced with b-mercaptoethanol, and subsequently, purified
fragments were assayed for their antibacterial activities. Sub-
fragment 1 had a molecular mass of 1,448 Da and an N-
terminal sequence of FKCRR, consistent with the predicted
sequence FKCRRWQWRm9, which represents the N-terminal
subfragment of the peptide (Fig. 5). The antibacterial activity
of this subfragment was not as potent as that of intact lactof-
erricin, having an MIC of 10 to 50 mM for most of the bacteria
tested (Table 3). Salmonella Salford and S. aureus remained
unaffected by concentrations up to 50 mM. Subfragment 2 had
a molecular mass of 1,718 Da and an N-terminal sequence of
KKLGA, consistent with the predicted sequence of KKLGA
PSITCVRRAFA, the C-terminal subfragment of the peptide
(Fig. 5). Subfragment 2 had weak antibacterial activity against
L. monocytogenes and both E. coli isolates, being effective in
the range of 40 to 60 mM. All other isolates remained unaf-
fected at concentrations up to 100 mM (Table 3).
DISCUSSION
These studies indicate that treatment of Lf with recombinant
chymosin at acidic pH can be used to generate an antibacterial
hydrolysate. Furthermore, by using an adaptation of the dis-
placement chromatography technique (21), a single-step ion-
exchange fractionation can yield a mixture of peptides identical
FIG. 4. Analytical RP-HPLC of ion-exchange and preparative HPLC frac-
tions of pepsin-hydrolyzed Lf that contain lactoferricin. Samples were brought to
0.1% TFA and 10 ml was injected onto a Vydac C18 column (25 by 0.46 cm [i.d.];
solvent A, 0.1% TFA; solvent B, 90% acetonitrile in 0.09% TFA; equilibration
was in 20% solvent B for 5 min; gradient, 20% solvent B to 50% solvent B over
40 min; flow rate, 1 ml/min). (A) Pepsin-hydrolyzed Lf. (B) Ion-exchange frac-
tion containing lactoferricin. (C) RP-HPLC-purified lactoferricin. The elution
position of lactoferricin is indicated with asterisks.
FIG. 5. The primary sequence of lactoferricin and CNBr-derived subfrag-
ments. The peptides were identified by N-terminal sequencing and MS. (A)
Lactoferricin, differing from lactoferricin B (7) by the presence of a C-terminal
alanine residue. (B) Subfragment 1, including the C-terminal homoserine lac-
tone. (C) Subfragment 2.
TABLE 2. Antibacterial activities of lactoferricin and its derivatives
Bacterium
MICa (mM) of lactoferricinb
Untreated Reduced CNBr-cleaved
Listeria monocytogenes 2 4 2
Escherichia coli L361 4 4 4
Salmonella Salford 4 4 4
Staphylococcus aureus 6 6 6
Escherichia coli O:9 6 8 6
Bacillus cereus 6 8 6
Pseudomonas fluorescens 8 6 8
a Defined as the minimum concentration required to inhibit bacterial growth,
measured by monitoring the absorbance at 620 nm.
b Peptide concentrations of 0, 2, 4, 6, 8, and 10 mM (0, 6.3, 12.5, 18.8, 25, and
31.3 mg/ml, respectively) were used.
TABLE 3. Antibacterial activities of fragments of lactoferricin
Bacterium
MICa (mM [mg/ml])
Subfragment 1 Subfragment 2
Listeria monocytogenes 10 (14.5)b 40 (68.7)c
Escherichia coli L361 10 (14.5)b 50 (85.9)c
Escherichia coli O:9 15 (21.7)d 60 (103.1)e
Bacillus cereus 20 (29.0)d .100 (.171.8)e
Pseudomonas fluorescens 50 (72.4)c .100 (.171.8)e
Salmonella Salford .50 (.72.4)c .100 (.171.8)e
Staphylococcus aureus .50 (.72.4)c .100 (.171.8)e
a Defined as the minimum concentration required to inhibit bacterial growth,
measured by monitoring the absorbance at 620 nm.
b Peptide concentrations of 0, 2, 4, 6, 8, and 10 mM were used.
c Peptide concentrations of 0, 10, 20, 30, 40, and 50 mM were used.
d Peptide concentrations of 0, 5, 10, 15, 20, and 25 mM were used.
e Peptide concentrations of 0, 20, 40, 60, 80, and 100 mM were used.
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or closely homologous to the antibacterial peptide Lf-cin B
characterized by Bellamy et al. (7). The antibacterial activities
of the peptides obtained by these methods are comparable to
that of Lf-cin B. The activity of the heterodimer (peptide 3)
was unaffected by structural additions at its C terminus, sug-
gesting that the region of activity for lactoferricin peptides lies
within their N-terminal sequences. Other studies undertaken
in this laboratory have observed that chymosin digestion of
apolactoferrin at slightly higher pH yields two large antibacte-
rial N-terminal fragments (Lf1–106 and Lf1–92). The iron-bind-
ing residues of Lf are well characterized (3), and it is specu-
lated that the fragments do not bind iron because they lack all
but one of the necessary iron-binding residues. Initial tests
suggest that the antibacterial activity of these larger fragments
(MIC5 160 mg/ml [13 mM]) closely resembles that of native Lf
(MIC 5 1 mg/ml [12.5 mM]).
From studies performed with chymosin and Lf at physiolog-
ical pH (37), it is unlikely that during the production of cheese
any antimicrobial peptides are produced by chymosin hydroly-
sis. Essentially all of the proteolysis that occurs during coagu-
lation is effected at a single site on k-casein (15). However, the
acids and enzymes of the mammalian gut that ingested Lf
encounters may provide an excellent in vivo environment for
the production of lactoferricins. In support of this, Tomita (39)
has isolated and characterized Lf-cin B excreted by Lf-fed rats,
suggesting a biological role for Lf as a precursor for antimi-
crobial lactoferricin peptides. The large-scale production of Lf
from cheese whey (16) or by fermentation (45) is well devel-
oped. Because Chymogen is a cheaper and readily obtainable
alternative to other aspartic proteases, it appears feasible for
dairy technologists to treat Lf with chymosin under acidic con-
ditions and produce large quantities of antibacterial hydroly-
sate. Technology developed for Lf purification could also be
used to isolate and purify antibacterially active peptides in
considerable quantities.
The isolation procedure used to obtain pepsin-generated
lactoferricin relied primarily on ion-exchange chromatography
to achieve a high yield and purity. The difference between the
lactoferricin isolated in this study (26 residues) and Lf-cin B
(25 residues) may be accounted for by the methods used to
characterize the peptides; Lf-cin B was characterized solely by
N-terminal sequencing (7), while the full sequence reported
here was determined by a combination of N-terminal sequenc-
ing and MS. It appears possible that if Lf-cin B were charac-
terized more extensively, its sequence may well have been
found to include a C-terminal alanine.
Each of the derivatives and subfragments of lactoferricin
retained at least some antibacterial activity. Against a range of
gram-positive and gram-negative bacteria, the activity of lacto-
ferricin did not vary appreciably, because all isolates were
inhibited by peptide concentrations within the range of 2 to 8
mM. The activity of reduced lactoferricin confirms the work of
Bellamy et al. (7), where a synthesized analog of Lf-cin B with
covalently blocked cysteine (acetamidomethyl-cysteine) resi-
dues matched the activity of pepsin-generated Lf-cin B. This is
in contrast to the findings made with bactenecin, a bovine
neutrophil dodecapeptide with an internal disulfide bond,
which lost all antibacterial activity on breaking its cyclic struc-
ture by replacement of disulfide-forming cysteines with ala-
nines (41). Breaking the cyclic structure of lactoferricin by
cleavage of the peptide at a point distal to its intact disulfide
bridge also resulted in no change to its antibacterial activity.
This suggests that neither a cyclic nor a linear structure for the
peptide is particularly critical for its effectiveness as an anti-
microbial agent. In a similar study, the lipopolysaccharide-
binding region of the 18-kDa cationic antibacterial protein
(CAP18) of rabbit neutrophils was synthesized as a 37-residue
peptide (CAP18106–142) (23). The sequence was found to be
antibacterial, and shorter peptides of CAP18106–142 were syn-
thesized to determine the antibacterial domain. However, two
truncated peptides based on the 37-residue sequence, equiva-
lent to CAP18106–114 and CAP18117–142, respectively, had no
activity either individually or in combination. This suggested
that the complete antimicrobial sequence must have specific
structural requirements not met by the shorter analogs (23).
As for CAP18106–142, the antibacterial activity of lactofer-
ricin, by these findings, could not be localized to a single re-
gion of the peptide. However, unlike the shorter analogs of
CAP18106–142, both fragments of lactoferricin retained antibac-
terial activity. This activity can be primarily attributed to the
first 10 N-terminal residues and partially to its remainder. At
physiological pH subfragment 1 has a higher positive charge
(five positive charges) than subfragment 2 (four positive charg-
es), and this charge difference may partially account for the
difference in antibacterial activity. It is doubtful, however, that
a high basic charge is solely responsible for the activity re-
corded for these peptides. Experiments which combined equi-
molar concentrations of subfragments 1 and 2 did not return
the activities obtained with CNBr-cleaved and oxidized lacto-
ferricin, suggesting that each subfragment contains an element
that must be brought into proximity with the other to achieve
the potent activity displayed by intact lactoferricin. Determi-
nation of the absolute nature of the peptide’s antibacterial
character would involve structural studies and further chemical
modification, initially directed at its positively charged resi-
dues.
Current opinion on the mechanism of action of basic anti-
bacterial peptides is focused on their interaction with the neg-
atively charged elements in the membranes of susceptible bac-
teria (29). These elements are lipopolysaccharide (LPS) in
gram-negative bacteria and lipotechoic acid in gram-positive
bacteria. Polymyxin B, a polycationic cyclic decapeptide with
an attached fatty acid is proposed to interact with LPS phos-
phate groups of the gram-negative outer membrane by ionic
attraction. It is reported to follow this by inserting its fatty acid
into the bilayer and distorting the lipid arrangement (36). Sub-
sequent work determined that while removal of the terminal
fatty acyl diaminobutyric acid of polymyxin B effectively abro-
gated its own antibacterial character, it was still capable of
sensitizing bacterial membranes to several antibiotics (31). It
seems likely that the nonspecific antibacterial activity of lacto-
ferricin and its subfragments is due to a similar interaction with
structures of a generalized nature on the surface of susceptible
microorganisms (e.g., LPS of gram-negative bacteria or lipo-
techoic acid of gram-positive species) and that this activity
involves a compromise of the membrane permeability barrier.
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